c-Abl inhibitors enable insights into the pathophysiology and neuroprotection in Parkinson’s disease
Parkinson’s disease (PD) is a progressive neurodegenerative disorder causing movement disabilities and several non-motor symptoms in afflicted patients. Recent studies in animal models of PD and analyses of brain specimen from PD patients revealed an increase in the level and activity of the non-rec...
Main Authors: | Dan Lindholm, Dan Duc Pham, Annunziata Cascone, Ove Eriksson, Krister Wennerberg, Mart Saarma |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2016-10-01
|
Series: | Frontiers in Aging Neuroscience |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fnagi.2016.00254/full |
Similar Items
-
EFFICACY OF NILOTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
by: Sajid Ali, et al.
Published: (2019-12-01) -
Coexistence of BCR-ABL1 Translocation and JAK2 V617F Mutation in a Patient with Chronic Myeloid Leukemia Under Long-term Treatment with Imatinib and Nilotinib:
A Case Report
by: Fatemeh Ranjbarnejad, et al.
Published: (2022-01-01) -
Insights from a rare myeloproliferative neoplasm with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations treated with nilotinib and ruxolitinib
by: Li Huo, et al.
Published: (2023-01-01) -
Extending the duration of response in chronic myelogenous leukemia: targeted therapy with sequential tyrosine kinase inhibitors
by: Michael G. Martin, et al.
Published: (2011-12-01) -
Transcripto BCR-ABL atípico en un paciente con leucemia mieloide crónica Atypical BCR-ABL transcript in a patient with chronic myeloid leukemia
by: Ana María Amor Vigil, et al.
Published: (2011-09-01)